The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.
The orally active platinum anti-tumour complex JM216[bis-acetatoamminedichlorocyclohexylamineplatinum(IV)] is at present in stage II clinical trials. A procedure for synthesising the complex labelled with 191Pt or 188Pt at the platinum centre has been developed. The purity (shown by HPLC) is 98% and the specific activity (0.3-0.4 Ci/kg) is enough for in vivo and in vitro studies.
Bates
P I
PI
Department of Medical Biophysics, University of Manchester, Medical School, UK.
Sharma
H L
HL
Murrer
B A
BA
Bernard
C F
CF
McAuliffe
C A
CA
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D007553:Isotope Labeling / Q000379:methods; D009944:Organoplatinum Compounds / Q000138:chemical synthesis*; D010984:Platinum / Q000737:chemistry*; D011786:Quality Control; D011868:Radioisotopes / Q000737:chemistry*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011868:Radioisotopes; D010984:Platinum; C081294:satraplatin